Related Experiment Video
Updated: Aug 6, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Dual-drug-loaded lipid-based formulation for colon cancer therapeutics: in vitro optimization and characterization
Rushikesh Sanjay Shewale1, Shyam Sudhakar Gomte1, Jyoti Bishlay2
1Department of Pharmaceutics, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Gujarat, India.
Objective:
The current investigation aims to fabricate, optimize and characterize dual-drug-loaded liposomes for the management of colon cancer.
Significance:
Lipid-based nanocarriers are versatile nanocarriers that facilitate the loading of both hydrophilic and hydrophobic therapeutic agents. The simultaneous delivery of capecitabine (CAP) and celecoxib (CEL) is anticipated to enhance anticancer efficacy against colon cancer.
Methods:
CAP-CEL-loaded liposomes (CAP-CEL-LIPs) were designed and optimized utilizing Box-Behnken Design (BBD). The optimized LIPs were characterized for particle size, polydispersity index (PDI), entrapment efficiency and morphological studies. In vitro drug release studies were conducted under both acidic and physiological conditions. Hemocompatibility was evaluated using the hemolysis assay and the stability of the LIPs was assessed over a duration of one month.
Results:
The optimized CAP-CEL-LIPs demonstrated a mean particle size of 130 ± 2.36 nm with a PDI of 0.162 ± 0.008, showing the homogeneous particle size distribution. The encapsulation efficiency for CAP and CEL was found to be 64.96 ± 2.81% and 92.23 ± 2.22%, respectively. SEM and TEM images revealed the spherical morphology of the developed LIPs. In vitro drug release investigations revealed a controlled release profile for both drugs under both acidic and physiological conditions. The hemolysis assay showed hemolysis rate of less than 2%, thereby confirming superior blood compatibility. Stability data indicated that LIPs remained stable for one-month. The developed CAP-CEL-LIPs showed significant cytotoxic potential with enhanced cellular uptake and apoptotic activity against colon cancer cells.
Conclusion:
The engineered CAP-CEL-LIPs could be a promising platform for managing colon cancer.
Related Concept Videos
Bioavailability Enhancement: Drug Permeability Enhancement
Modified-Release Drug Delivery Systems: Site-Targeted
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Site-Targeted Drug Delivery Systems: Polymeric Carriers

